Skip to main content
SpringerLink
Log in

The relationship between visfatin and serum concentrations of C-reactive protein, interleukin 6 in patients with metabolic syndrome

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Aim

To evaluate the relationship between inflammatory and pro inflammatory markers, with obesity and visceral adiposity in male subjects with or without metabolic syndrome (MS).

Subjects and methods

A total of 37 patients with MS and 37 age matched controls were included (mean age 46.35 ± 1.6 years). MS was defined by the criteria of the international diabetes federation 2005. Anthropometric and biochemical profiles, including high-sensitivity C-reactive protein (Hs-CRP), visfatin and interleukin 6 (IL-6), were measured. Data were compared between groups by using t test. Pearson’s correlation was used to evaluate the relationship between variables. P values less than 0.05 were considered as statistically significant.

Results

In patients with MS, CRP and IL-6 were significantly correlated with body mass index, waist circumference and waist to hip ratio. Visfatin levels were significantly lower in patients with MS compared to controls (log visfatin: 1.74 ± 0.27 vs. 1.86 ± 0.13 ng/ml, MS vs. control group respectively). We cannot find any significant correlation between visfatin, CRP and IL-6. Also there were no correlation between visfatin levels and any anthropometric parameters in patients with MS or control groups.

Conclusion

Serum visfatin was lower in patients with MS. Therefore it seems that visfatin could not be considered as a pro inflammatory adipocytokine in MS. The positive associations of obesity and visceral adiposity with elevated CRP and IL-6 levels suggest the importance of reducing visceral adiposity to prevent the risk of coronary disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Abbreviations

BMI:

Body mass index

BP:

Blood pressure

CHD:

Coronary heart disease

CRP:

C-reactive protein

CVD:

Cardiovascular diseases

ELISA:

Enzyme-linked immunosorbent assay

EIA:

Enzyme immunoassay

FPG:

Fasting plasma glucose

Hs-CRP:

High-sensitivity C-reactive protein

IL-6:

Interleukin 6

IDF:

International diabetes federation

MS:

Metabolic syndrome

TG:

Triglyceride

TNF-α:

Tumor necrosis factor-alpha

TLGS:

Tehran lipid and glucose study

WHR:

Waist to hip ratio

WC:

Waist circumference

References

  1. Lorenzo C, Williams K, Hunt KJ, Haffner SM (2007) The national cholesterol education program-adult treatment panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 30(1):8

    Article  PubMed  Google Scholar 

  2. Alberti KG, Zimmet P, Shaw J (2005) The metabolic syndrome—a new worldwide definition. Lancet 366(9491):1059

    Article  PubMed  Google Scholar 

  3. Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J (2005) The metabolic syndrome: a global public health problem and a new definition. Vascular 7:8

    Google Scholar 

  4. Maury E, Brichard S (2010) Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 314(1):1–16

    Article  CAS  PubMed  Google Scholar 

  5. Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Alméras N et al (2000) Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 102(2):179–184

    Article  CAS  PubMed  Google Scholar 

  6. Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD et al (2004) Intra-abdominal fat is a major determinant of the national cholesterol education program adult treatment panel III criteria for the metabolic syndrome. Diabetes 53(8):2087–2094

    Article  CAS  PubMed  Google Scholar 

  7. Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37(12):1595

    Article  CAS  PubMed  Google Scholar 

  8. Koh KK, Han SH, Quon MJ (2005) Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. J Am Coll Cardiol 46(11):1978–1985

    Article  CAS  PubMed  Google Scholar 

  9. Shoelson SE, Lee J, Goldfine AB (2006) Inflammation and insulin resistance. J Clin Invest 116(7):1793

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Juge-Aubry CE, Henrichot E, Meier CA (2005) Adipose tissue: a regulator of inflammation. Best Pract Res Clin Endocrinol Metab 19(4):547–566

    Article  CAS  PubMed  Google Scholar 

  11. Rifai N, Ridker PM (2001) High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem 47(3):403

    CAS  PubMed  Google Scholar 

  12. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR (2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347(20):1557–1565

    Article  CAS  PubMed  Google Scholar 

  13. Devaraj S, Singh U, Jialal I (2009) Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol 20(3):182

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW (1999) C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19(4):972–978

    Article  CAS  PubMed  Google Scholar 

  15. Bastard JP, Jardel C, Delattre J, Hainque B, Bruckert E, Oberlin F (1999) Evidence for a link between adipose tissue interleukin-6 content and serum C-reactive protein concentrations in obese subjects. Circulation 99(16):2219–2222

    Article  Google Scholar 

  16. Ognjanovic S, Bao S, Yamamoto S, Garibay-Tupas J, Samal B, Bryant-Greenwood G (2001) Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. J Mol Endocrinol 26(2):107–117

    Article  CAS  PubMed  Google Scholar 

  17. Kralisch S, Klein J, Lossner U, Bluher M, Paschke R, Stumvoll M et al (2005) Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 289(4):E586–E590

    Article  CAS  PubMed  Google Scholar 

  18. Kralisch S, Klein J, Lossner U, Bluher M, Paschke R, Stumvoll M et al (2005) Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes. J Endocrinol 185(3):R1

    Article  CAS  PubMed  Google Scholar 

  19. Ahima RS (2006) Adipose tissue as an endocrine organ. Obesity 14:242S–249S

    Article  CAS  PubMed  Google Scholar 

  20. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K et al (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307(5708):426

    Article  CAS  PubMed  Google Scholar 

  21. Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R et al (2006) Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 91(8):3165

    Article  CAS  PubMed  Google Scholar 

  22. Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B (2006) Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 91(4):1578

    Article  CAS  PubMed  Google Scholar 

  23. Sandeep S, Velmurugan K, Deepa R, Mohan V (2007) Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians. Metabolism 56(4):565–570

    Article  CAS  PubMed  Google Scholar 

  24. Berndt J, Klöting N, Kralisch S, Kovacs P, Fasshauer M, Schön MR et al (2005) Plasma visfatin concentrations and fat depot–specific mRNA expression in humans. Diabetes 54(10):2911

    Article  CAS  PubMed  Google Scholar 

  25. Zahorska-Markiewicz B, Olszanecka-Glinianowicz M, Janowska J, Kocelak P, Semik-Grabarczyk E, Holecki M et al (2007) Serum concentration of visfatin in obese women. Metabolism 56(8):1131–1134

    Article  CAS  PubMed  Google Scholar 

  26. Jin H, Jiang B, Tang J, Lu W, Wang W, Zhou L et al (2008) Serum visfatin concentrations in obese adolescents and its correlation with age and high-density lipoprotein cholesterol. Diabetes Res Clin Pract 79(3):412–418

    Article  CAS  PubMed  Google Scholar 

  27. Davutoglu M, Ozkaya M, Guler E, Garipardic M, Gursoy H, Karabiber H et al (2009) Plasma visfatin concentrations in childhood obesity: relationships with insulin resistance and anthropometric indices. Swiss Med Wkly 139(1–2):22–27

    PubMed  Google Scholar 

  28. Revollo JR, Körner A, Mills KF, Satoh A, Wang T, Garten A et al (2007) Nampt/PBEF/visfatin regulates insulin secretion in [beta] cells as a systemic NAD biosynthetic enzyme. Cell Metab 6(5):363–375

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Saddi-Rosa P, Oliveira CSV, Giuffrida FMA, Reis AF (2010) Visfatin, glucose metabolism and vascular disease: a review of evidence. Diabetol Metab Syndr 2(1):1–6

    Article  Google Scholar 

  30. Azizi F, Rahmani M, Emami H, Mirmiran P, Hajipour R, Madjid M et al (2002) Cardiovascular risk factors in an Iranian urban population: Tehran lipid and glucose study (phase 1). Soz Praventivmed 47(6):408–426

    Article  PubMed  Google Scholar 

  31. Azizi F, Ghanbarian A, Momenan AA, Hadaegh F, Mirmiran P, Hedayati M et al (2009) Prevention of non-communicable disease in a population in nutrition transition: Tehran lipid and glucose study phase II. Trials 10(5):19166627

    Google Scholar 

  32. Seo JA, Jang ES, Kim BG, Ryu OH, Kim HY, Lee KW et al (2008) Plasma visfatin levels are positively associated with circulating interleukin-6 in apparently healthy Korean women. Diabetes Res Clin Pract 79(1):108–111

    Article  CAS  PubMed  Google Scholar 

  33. Kim JH, Kim SH, Im JA, Lee DC (2010) The relationship between visfatin and metabolic syndrome in postmenopausal women. Maturitas 67(1):67–71

    Article  CAS  PubMed  Google Scholar 

  34. Zhong M, Tan H, Gong H, Wang S, Zhang Y, Zhang W (2008) Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol 69(6):878–884

    Article  CAS  Google Scholar 

  35. Filippatos T, Derdemezis C, Gazi I, Lagos K, Kiortsis D, Tselepis A et al (2008) Increased plasma visfatin levels in subjects with the metabolic syndrome. Eur J Clin Invest 38(1):71–72

    Article  CAS  PubMed  Google Scholar 

  36. Lin CC, Lai MM, Li TC, Li CI, Liu CS, Chen CC et al (2009) Relationship between serum retinol-binding protein 4 and visfatin and the metabolic syndrome. Diabetes Res Clin Pract 85(1):24–29

    Article  CAS  PubMed  Google Scholar 

  37. Olszanecka-Glinianowicz M, Kocełak P, Janowska J, Skorupa A, Nylec M, Zahorska-Markiewicz B (2011) Plasma visfatin and tumor necrosis factor-alpha (TNF-a) levels in metabolic syndrome. Kardiol Polska 69(8):802

    PubMed  Google Scholar 

  38. Chen CC, Li TC, Li CI, Liu CS, Lin WY, Wu MT et al (2007) The relationship between visfatin levels and anthropometric and metabolic parameters: association with cholesterol levels in women. Metabolism 56(9):1216–1220

    Article  CAS  PubMed  Google Scholar 

  39. Wen Y, Wang H, Wu J, Lu H, Hu XF, Cianflone K (2006) Effects of fatty acid regulation on visfatin gene expression in adipocytes. Chin Med J (Engl) 119(20):1701

    CAS  Google Scholar 

  40. MacLaren R, Cui W, Cianflone K (2007) Visfatin expression is hormonally regulated by metabolic and sex hormones in 3T3-L1 pre-adipocytes and adipocytes. Diabetes Obes Metab 9(4):490–497

    Article  CAS  PubMed  Google Scholar 

  41. Nüsken KD, Niisken E, Petrasch M, Rauh M, Dötsch J (2007) Preanalytical influences on the measurement of visfatin by enzyme immuno assay. Clin Chim Acta 382(1–2):154–156

    Article  PubMed  Google Scholar 

  42. Körner A, Garten A, Blüher M, Tauscher R, Kratzsch J, Kiess W (2007) Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab 92(12):4783–4791

    Article  PubMed  Google Scholar 

  43. Mohamed-Ali V, Pinkney J, Coppack S (1998) Adipose tissue as an endocrine and paracrine organ. Int J Obes 22:1145–1158

    Article  CAS  Google Scholar 

  44. Pickup J, Mattock M, Chusney G, Burt D (1997) NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40(11):1286–1292

    Article  CAS  PubMed  Google Scholar 

  45. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V (2000) Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 148(2):209–214

    Article  CAS  PubMed  Google Scholar 

  46. Florez H, Castillo-Florez S, Mendez A, Casanova-Romero P, Larreal-Urdaneta C, Lee D et al (2006) C-reactive protein is elevated in obese patients with the metabolic syndrome. Diabetes Res Clin Pract 71(1):92–100

    Article  CAS  PubMed  Google Scholar 

  47. Lyon CJ, Law RE, Hsueh WA (2003) Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 144(6):2195–2200

    Article  CAS  PubMed  Google Scholar 

  48. Matsuzawa Y, Funahashi T, Nakamura T (1999) Molecular mechanism of metabolic syndrome x: contribution of adipocytokines· adipocyte-derived bioactive substances. Ann N Y Acad Sci 892(1):146–154

    Article  CAS  PubMed  Google Scholar 

  49. Clement K, Viguerie N, Poitou C, Carette C, Pelloux V, Curat CA et al (2004) Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. FASEB J 18(14):1657–1669

    Article  CAS  PubMed  Google Scholar 

  50. Dandona P, Aljada A, Bandyopadhyay A (2004) Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 25(1):4–7

    Article  CAS  PubMed  Google Scholar 

  51. Fernández-Real JM, Ricart W (2003) Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 24(3):278–301

    Article  PubMed  Google Scholar 

  52. Arnaud C, Burger F, Steffens S, Veillard NR, Nguyen TH, Trono D et al (2005) Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes. Arterioscler Thromb Vasc Biol 25(6):1231–1236

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank all persons who participated in this study. We also thank Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences for this collaboration within the framework of the Tehran lipid and glucose study (TLGS). This piece of research was granted by Tehran University of Medical Sciences, Tehran, Iran (grant number: 6068).

Author information

Authors and Affiliations

  1. Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, No#44, Hojjatdoost St, Naderi Ave, Keshavarz Bld, Tehran, Iran

    M. J. Hosseinzadeh-Attar

  2. Department of Nutrition and Biochemistry, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

    A. Golpaie & M. Foroughi

  3. Obesity Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    F. Hosseinpanah

  4. Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    S. Zahediasl

  5. Obesity Research Center and Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Science, Tehran, Iran

    F. Azizi

Authors
  1. M. J. Hosseinzadeh-Attar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Golpaie
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Foroughi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. Hosseinpanah
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Zahediasl
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F. Azizi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. J. Hosseinzadeh-Attar.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The study was approved by the ethics committee of Shahid Beheshti University of Medical Sciences.

Informed consent

Written informed consent was obtained from all subjects.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hosseinzadeh-Attar, M.J., Golpaie, A., Foroughi, M. et al. The relationship between visfatin and serum concentrations of C-reactive protein, interleukin 6 in patients with metabolic syndrome. J Endocrinol Invest 39, 917–922 (2016). https://doi.org/10.1007/s40618-016-0457-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-016-0457-1

Keywords

Search

Navigation